iZafe Group

iZafe Group EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of iZafe Group (IZAFE B.ST) as of Nov 19, 2026 is -18.39 M SEK. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -15.50 M SEK — a change of 18.68% (lower).

EBITDA

-18.39 MSEK

YoY

18.68%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of iZafe Group is 2025 -18.39 M SEK. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of iZafe Group was 2024 -15.50 M SEK. It decreases by 18.68% lower compared to the previous year.

The iZafe Group EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
-10.17 M SEK
Jan 1, 2019
-16.83 M SEK
Jan 1, 2020
-6.74 M SEK
Jan 1, 2021
-28.42 M SEK
Jan 1, 2022
-19.04 M SEK
Jan 1, 2023
-12.49 M SEK
Jan 1, 2024
-15.50 M SEK
Jan 1, 2025
-18.39 M SEK
The iZafe Group EBITDA history
YEAREBITDAYoY
-18.39 MSEK+18.68%
-15.50 MSEK+24.06%
-12.49 MSEK-34.40%
-19.04 MSEK-33.02%
-28.42 MSEK+321.58%
-6.74 MSEK-59.95%
-16.83 MSEK+65.53%
-10.17 MSEK+166.34%
-3.82 MSEK-23.77%
-5.01 MSEK+831.50%
-537,658.00SEK-52.03%
-1.12 MSEK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

iZafe Group Stock analysis

What does iZafe Group do? iZafe Group AB develops medical and digital security solutions, including Dosell, a patented drug dispenser for home medication with remote monitoring, and MediKoll, an app providing medication side effect and allergy information. The company serves pharmaceutical companies, hospitals, care homes, and pharmacies in the global market. Its products target patients and healthcare providers seeking secure, remote medication management and personalized health information. Dosell is under development as a home medication solution, while MediKoll offers real-time data on medication reactions. The firm's revenue comes from selling these digital tools to healthcare institutions and pharmaceutical partners, focusing on improving patient safety and reducing medication errors through technology. iZafe Group AB's business model relies on the global healthcare sector's demand for innovative digital tools. The company's offerings are tailored for pharmaceutical firms, hospitals, care homes, and pharmacies, leveraging remote monitoring capabilities to address medication management challenges in home and clinical settings. iZafe Group is one of the most popular companies on Eulerpool.

Frequently Asked Questions about iZafe Group stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of iZafe Group is -18.39 M SEK in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of iZafe Group changed from -15.50 M SEK to -18.39 M SEK, representing a 18.68% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) iZafe Group since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s iZafe Group historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — iZafe Group

All Key Metrics — iZafe Group